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Colorectal cancer is the third most common malignancy in the
‘developed’ world, after lung and breast cancer, and causes
approximately 16000 deaths per year in England and Wales. It
usually occurs in the seventh or eight decade and has a similar
overall incidence in the sexes. Despite improvements in early
diagnosis, over recent years up to 30% of large bowel cancers still
present as emergencies with obstruction or perforation and
approximately 30% present late with metastatic disease.
Despite significant advancements in diagnostics, surgical
technique, perioperative and postoperative therapies, many
sceptics still suggest that the mortality from this disease has
changed very little over the last few decades. The two preceding
articles in this supplement of the British Journal of Cancer identify
considerable improvements with regard to our management of
patients with colorectal cancer in the United Kingdom. These
papers report an increasing incidence rate of the disease but more
important is the improvement in survival figures for colon cancer
in England and Wales with a 40% 5-year survival rate in the late
1980s compared with 48% in the late 1990s. The improvement for
rectal cancer is even more marked than for colon cancer. Although
the absolute values of 5-year survival are inflated (as discussed by
the authors) due to patients excluded from their analysis having a
shorter survival period, the survival trends are most striking and
encouraging.
So why has the incidence of colorectal cancer increased at the
end of the 20th century? This is difficult to fully explain but there
are a number of factors that may have contributed. Colonoscopic
screening of high-risk individuals with a strong predisposition for
colorectal cancer such as a strong family history, adenomatous
polyps and inflammatory bowel disease has undoubtedly improved
the detection rate of the disease (Atkin et al, 2002). Increased
public awareness of the disease along with more willingness to
report symptoms to the family doctor may be a significant factor,
with consequent earlier presentation of cases. Dietary factors may
be important with those consuming high meat, low-fibre diets felt
to be at greater risk. Other lifestyle factors such as obesity, falling
rates of physical activity and increasing consumption of alcohol
may also have played a part.
And why have survival rates improved towards the latter part of
the 20th century? Again increased public awareness leading to
earlier diagnosis of better stage tumours is important. The
introduction of the multidisciplinary team approach to the
management of all patients with colorectal cancer has been
instrumental in improving the decision making and eventual
outcome of these patients (Kelly et al, 2003). Improved training
workshops and specialisation of general surgeons has occurred
with advances in surgical techniques, particularly in relation to
rectal cancer, and this has resulted in the adoption of meticulous
surgery in the form of total mesorectal excision (TME) with lower
local recurrence rates and improved survival (MacFarlane et al,
1993). Similarly, advances in more effective adjuvant chemo- and
radiotherapy have had a significant part to play, although the
availability of many of the expensive adjuvant chemotherapeutic
agents remains a subject of debate in the United Kingdom (Camma `
et al, 2000; Tebbutt et al, 2002). Over the past 20 years there has
been much enthusiasm in support of liver resection in patients
with metastatic colorectal cancer with many centres reporting
excellent results. Regular imaging and detection of operable liver
lesions during staging and follow-up of colorectal cancer has also
resulted in some survival benefit (Garden et al, 2006).
It is disappointing that survival rates among the more affluent
remain better than among the more deprived. We agree with the
authors that this suggests that more affluent patients have
probably benefited preferentially from progress in early diagnostic
procedures and in access to optimal treatment over this period,
highlighting an important ongoing challenge for health services.
Despite the encouraging survival trends there is still room for
improvement, particularly, as many of our American and European
counterparts quote survival figures over 50% (O’Connell et al,
2004). The Department of Health has suggested that these UK
statistics do not reflect any progress from the significant
investment in cancer care since the publication of the NHS Cancer
Plan in 2000. Government targets have been introduced in an
attempt to identify ‘high risk or alarm symptoms’ with the aim of
reducing delays between presentation, diagnosis and treatment.
Time will tell if these target guidelines will bring any long-term
survival benefits to patients in the United Kingdom.
Over the next few years bowel cancer screening by means of
faecal occult blood (FOB) testing is being phased in throughout
England and Wales. It is hoped that by implementing such a
national population screening programme, many earlier stage
cancers will be detected and this should reduce disease specific
mortality as has been shown in several previous randomised
controlled trials (Mandel et al, 1993; Hardcastle et al, 1996;
Kronborg et al, 1996).
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rectal cancer, important new developments in the management of
the disease allow us to be more optimistic about continuing
improved survival rates for colorectal cancer into the 21st century.
The outstanding challenge for health services will be to ensure that
the projected widening of the deprivation gap does not become a
reality and to develop strategies to close this gap in forthcoming
years.
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